TY - JOUR T1 - â–¼Memantine for dementia? JF - Drug and Therapeutics Bulletin JO - Drug Ther Bull SP - 73 LP - 76 DO - 10.1136/dtb.2003.411073 VL - 41 IS - 10 A2 - , Y1 - 2003/10/01 UR - http://dtb.bmj.com/content/41/10/73.abstract N2 - Relevant BNF section: 4.11â–¼Memantine (Ebixa - Lundbeck Ltd), an oral medicine, is available in the UK for treating "patients with moderately severe to severe Alzheimer's disease". It differs from other licensed dementia medicines in that it is an N-methyl-D-aspartate (NMDA) receptor antagonist. The company has claimed that, with memantine therapy, "improvements in activities of daily living help patients to maintain a degree of independence and be easier to care for, potentially avoiding the need for nursing home care". We assess the efficacy of memantine for dementia and discuss its place in the management of patients with Alzheimer's disease. ER -